Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (313)	5/13/2004 12:25:05 PM
From: VIXandMore	Respond to of 370

Vion Reports 2004 First Quarter Financial Results NEW HAVEN, Conn., May 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq Smallcap: VION - News) today announced results for the three-month period ended March 31, 2004. The Company reported a net loss of $3.3 million, or $0.07 per share, for the three-month period ended March 31, 2004, compared with a net loss of $2.4 million, or $0.08 per share, for the same period in 2003. Weighted-average common shares outstanding for the three-month periods ended March 31, 2004 and 2003 were 47.3 million and 28.9 million, respectively. Total operating expenses were $3.4 million and $2.5 million for the three-month periods ended March 31, 2004 and 2003, respectively. The increase in operating expenses was primarily due to higher patient enrollment in clinical trials of Triapine® and CLORETAZINE(TM) (VNP40101M) and additional drug production expense. The Company reported ending the quarter with $51.2 million in cash, cash equivalents and short-term investments, including net proceeds of $32.9 million from a private placement of common stock and warrants completed in February 2004 as well as proceeds of $5.6 million from the issuance of 2,337,154 shares of its common stock upon exercises of warrants issued in connection with two private placements in 2003. Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer. Vion has two agents in Phase II clinical trials: Triapine®, a potent inhibitor of a key step in DNA synthesis and CLORETAZINE(TM) (VNP40101M), a unique sulfonylhydrazine alkylating agent. Vion is also developing and has an option to license several heterocyclic hydrazones which have demonstrated potent anti-tumor activity in preclinical studies. Additional agents in preclinical studies include: KS119, a hypoxia-selective compound from the sulfonylhydrazine class and TAPET®, a modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

To: Jim Oravetz who wrote (313)	6/2/2004 11:50:51 AM
From: Jim Oravetz	Respond to of 370

VION Announces Initiation of a Phase II Trial Of CLORETAZINE (VNP40101M) In Patients With Primary Brain Tumors June 1 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. announced today that a Phase II trial of its anticancer agent CLORETAZINE(TM) (VNP40101M) has been initiated at the Brain Tumor Center of the Duke University Comprehensive Cancer Center, Durham, North Carolina. The study will assess the activity and toxicity of CLORETAZINE(TM) (VNP40101M) in adult patients with recurrent gliomas (gliomas are cancers that originate in the brain). Dr. Mario Sznol, Vice President, Clinical Affairs, stated, "Current treatment for glioma, which is often a devastating disease, is inadequate, and we are hopeful that CLORETAZINE(TM) (VNP40101M) can have meaningful effects in these patients. In preclinical studies, CLORETAZINE(TM) (VNP40101M) was shown to distribute well into the brain, and also demonstrated potential advantages over several other alkylating agents, which are the current standard of treatment for most gliomas. We are fortunate to have developed a preclinical and clinical collaboration with one of the leading centers for research and treatment of brain tumors, Duke University, to advance the studies of our agent." CLORETAZINE(TM) (VNP40101M) is a novel DNA-damaging alkylating agent with broad spectrum anti-tumor activity in preclinical studies. Two Phase I trials in solid tumors, which have completed accrual, have investigated the safety profile, maximum tolerated dose and schedule for Phase II trials, as well as the pharmacokinetic parameters (blood levels) of the agent. Vion plans additional Phase II trials in other solid tumors, and has an ongoing clinical development program in hematologic malignancies. Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer. Vion has two agents in Phase II clinical trials: Triapine(R), a potent inhibitor of a key step in DNA synthesis and CLORETAZINE(TM) (VNP40101M), a unique sulfonylhydrazine alkylating agent. Vion is also developing and has an option to license several heterocyclic hydrazones which have demonstrated potent anti-tumor activity in preclinical studies. Additional agents in preclinical studies include: KS119, a hypoxia-selective compound from the sulfonylhydrazine class and TAPET(R), a modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at vionpharm.com .